|D009209||Myofascial Pain Syndromes NIH||0.58|
There is one clinical trial.
This is a pilot study to investigate the safety and feasibility of rhDNase1 and its impact on neutrophil extracellular traps (NETs) in COVID-19 infected patients.
Description: Rate of all adverse events, rate of serious adverse events, rate of grade 3/4/5 adverse events, rate of drug-related adverse events.Measure: Safety of inhaled rhDNase1 in non-ventilated COVID-19 patients by reporting of adverse events Time: 9 months
Description: Time elapsed between the study opening date and the first patient enrolment date.Measure: Time to first study participant enrolment Time: Up to 2 weeks
Description: Number of patients enrolled per week following the start of the study.Measure: Enrolment rate Time: Up to 9 months
Description: Number of patients meeting eligibility through inclusion and exclusion criteria that are consented and enrolled into the study, as compared to the total number of patients meeting criteria (enrolled and non-enrolled).Measure: Eligible patient consent rate Time: Up to 9 months
Description: Percentage of doses missed compared to completed, including reasons for missed doses, per patient.Measure: Completeness of drug delivery Time: Up to 9 months
Description: Percentage of tests or procedures missed compared to completed, per patient.Measure: Completeness of study-specific tests or procedures Time: Up to 9 months
Description: Percentage of missed data compared to completed data, per patient.Measure: Completeness of data collection Time: Up to 9 months
Description: Extent of hypoxia rate is defined as the number of patients requiring supplemental oxygen, categorized by type of oxygen requirement.Measure: Hypoxia rate Time: Up to 9 months
Description: Type of oxygen in FiO2 requirements needed by each patient in the study, if applicable.Measure: Supplemental oxygen requirement type Time: Up to 9 months
Description: Number of patients progressing to requiring intubation and mechanical ventilation.Measure: Progression to mechanical ventilation rate Time: Up to 9 months
Description: Duration in days, for patients requiring intubation and mechanical ventilation, if applicable.Measure: Duration of mechanical ventilation Time: Up to 9 months
Description: Number of patients who show progression on imaging suggestive of ARDS such as bilateral lung involvement, as reviewed by study's thoracic radiologist.Measure: Radiological progression Time: Up to 9 months
Description: Number of patients with renal dysfunction, classified by stage (1, 2 or 3).Measure: Renal dysfunction rate Time: Up to 9 months
Description: Extent of change in creatinine from baseline.Measure: Renal dysfunction extent Time: Up to 9 months
Description: Number of patients contracting secondary bacterial infections (pneumonia, bacteremia and other).Measure: Secondary bacterial infections rate Time: Up to 9 months
Description: In days, length of stay in the ICU.Measure: Duration of ICU admission Time: Up to 9 months
Description: Time elapsed between enrolment into the study (at admission), and endpoint (discharge from ICU or in-hospital mortality).Measure: Time to hospital discharge or in-hospital mortality Time: Up to 9 months
Description: Defined as number of days between first positive PCR test and last positive PCR test, usually done by nasopharyngeal swabs. Tests will be performed as mandated by standard of care only.Measure: Length of PCR positivity Time: Up to 9 months
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports